Publications by Idar Lygren
86 publications found
Original articles
Cytokine Levels After Consumption of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan™ , in Patients with Crohn's Disease and Ulcerative Colitis in a Randomized Single-Blinded Placebo-Controlled Study
Scand J Immunol, 84 (6), 323-331
DOI 10.1111/sji.12476, PubMed 27588816
Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSanTM, on Symptoms, Fatigue and Quality of Life in Patients with Crohn's Disease in a Randomized Single-Blinded Placebo Controlled Study
PLoS One, 11 (7), e0159288
DOI 10.1371/journal.pone.0159288, PubMed 27415795
Effect of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan™, on Symptoms, Fatigue and Quality of Life in Patients with Ulcerative Colitis in a Randomized Single-Blinded Placebo Controlled Study
PLoS One, 11 (3), e0150191
DOI 10.1371/journal.pone.0150191, PubMed 26933886
Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy
Inflamm Bowel Dis, 19 (10), 2111-7
DOI 10.1097/MIB.0b013e31829b2a37, PubMed 23883959
Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: possible implication for TLR4-signalling and chronic immune activation
Innate Immun, 19 (3), 290-7
DOI 10.1177/1753425912461042, PubMed 23070967
Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study
J Crohns Colitis, 6 (4), 441-53
DOI 10.1016/j.crohns.2011.10.001, PubMed 22398064
Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn's disease
Scand J Immunol, 73 (1), 66-75
DOI 10.1111/j.1365-3083.2010.02477.x, PubMed 21129005
Reduced platelet function and role of drugs in acute gastrointestinal bleeding
Basic Clin Pharmacol Toxicol, 108 (3), 194-201
DOI 10.1111/j.1742-7843.2010.00643.x, PubMed 21118353
[Risk factors for peptic ulcer bleeding]
Tidsskr Nor Laegeforen, 130 (11), 1135-9
DOI 10.4045/tidsskr.08.0693, PubMed 20531499
Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease
Inflamm Bowel Dis, 15 (3), 406-14
DOI 10.1002/ibd.20781, PubMed 19009607
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
Scand J Gastroenterol, 44 (4), 431-40
DOI 10.1080/00365520802600961, PubMed 19101844
Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years
J Crohns Colitis, 3 (2), 92-9
DOI 10.1016/j.crohns.2008.11.002, PubMed 21172251
C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study
Gut, 57 (11), 1518-23
DOI 10.1136/gut.2007.146357, PubMed 18566104
MRI of the small bowel with oral contrast or nasojejunal intubation in Crohn's disease: randomized comparison of patient acceptance
Scand J Gastroenterol, 43 (1), 44-51
DOI 10.1080/00365520701494813, PubMed 18158695
Transcatheter arterial embolization in the management of bleeding duodenal ulcers: a 5.5-year retrospective study of treatment and outcome
Scand J Gastroenterol, 43 (2), 217-22
DOI 10.1080/00365520701676443, PubMed 18224566
Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study
Clin Gastroenterol Hepatol, 5 (12), 1430-8
DOI 10.1016/j.cgh.2007.09.002, PubMed 18054751
Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study
Am J Gastroenterol, 102 (9), 1955-63
DOI 10.1111/j.1572-0241.2007.01368.x, PubMed 17573793
A prospective randomized comparison between two MRI studies of the small bowel in Crohn's disease, the oral contrast method and MR enteroclysis
Eur Radiol, 17 (9), 2294-301
DOI 10.1007/s00330-007-0648-4, PubMed 17483955
Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study)
Scand J Gastroenterol, 42 (5), 602-10
DOI 10.1080/00365520601076124, PubMed 17454881
Increased skewing of X chromosome inactivation with age in both blood and buccal cells
Cytogenet Genome Res, 116 (1-2), 24-8
DOI 10.1159/000097414, PubMed 17268174
Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study)
Scand J Gastroenterol, 41 (9), 1037-43
DOI 10.1080/00365520600554527, PubMed 16938716
Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study)
Inflamm Bowel Dis, 12 (7), 543-50
DOI 10.1097/01.MIB.0000225339.91484.fc, PubMed 16804390
Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease
Inflamm Bowel Dis, 12 (5), 402-12
DOI 10.1097/01.MIB.0000218762.61217.4a, PubMed 16670530
Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis
Eur J Gastroenterol Hepatol, 17 (10), 1037-45
DOI 10.1097/00042737-200510000-00006, PubMed 16148548
Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms
Inflamm Bowel Dis, 11 (10), 909-18
DOI 10.1097/01.mib.0000179467.01748.99, PubMed 16189421
Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis
Scand J Gastroenterol, 39 (4), 365-73
DOI 10.1080/00365520310008386, PubMed 15125469
Bowel MR imaging with oral Gastrografin: an experimental study with healthy volunteers
Eur Radiol, 13 (1), 100-6
DOI 10.1007/s00330-002-1528-6, PubMed 12541116
Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1)
Eur J Gastroenterol Hepatol, 14 (3), 243-8
DOI 10.1097/00042737-200203000-00007, PubMed 11953688
Removal of IgG from normal plasma and plasma from untreated patients with active Crohn's disease--effect on levels of contact factors
Scand J Clin Lab Invest, 60 (3), 237-45
DOI 10.1080/003655100750044893, PubMed 10885496
[Treatment of Helicobacter pylori infection]
Tidsskr Nor Laegeforen, 118 (29), 4511-4
PubMed 9889634
Intestinal IgA- and IgM-producing cells are not decreased in marathon runners
Int J Sports Med, 19 (6), 425-31
DOI 10.1055/s-2007-971940, PubMed 9774211
Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93
Scand J Gastroenterol, 32 (10), 1005-12
DOI 10.3109/00365529709011217, PubMed 9361173
Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway
Gut, 40 (3), 328-32
DOI 10.1136/gut.40.3.328, PubMed 9135520
Development and evaluation of written patient information for endoscopic procedures
Endoscopy, 29 (1), 23-6
DOI 10.1055/s-2007-1004056, PubMed 9083732
Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists
Scand J Gastroenterol, 31 (4), 355-61
DOI 10.3109/00365529609006410, PubMed 8726303
Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists
Scand J Gastroenterol, 31 (4), 362-6
DOI 10.3109/00365529609006411, PubMed 8726304
Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists
Digestion, 56 (5), 377-81
DOI 10.1159/000201262, PubMed 8549880
[Follow-up of chronic inflammatory bowel disease. A 10-year material]
Tidsskr Nor Laegeforen, 114 (6), 674-7
PubMed 8191448
GASTROINTESTINAL-BLEEDING ASSOCIATED WITH THE USE OF NONSTEROIDAL, ANTIINFLAMMATORY DRUGS - SYMPTOMATOLOGY AND CLINICAL COURSE
Agents Actions, C86-C87
Gastrointestinal bleeding associated with the use of non-steroidal, anti-inflammatory drugs--symptomatology and clinical course
Agents Actions, Spec No, C86-7
PubMed 1442342
Gastrointestinal bleeding: dyspeptic symptoms and clinical course in relation to use of non-steroidal antiinflammatory drugs
Scand J Rheumatol, 20 (5), 366-9
DOI 10.3109/03009749109096813, PubMed 1947900
[Endoscopic retrograde cholangio-pancreatography in suspected acute gallstone pancreatitis]
Tidsskr Nor Laegeforen, 110 (10), 1216-8
PubMed 2185580
Vasoactive intestinal peptide in sepsis and shock
Ann N Y Acad Sci, 527, 536-45
DOI 10.1111/j.1749-6632.1988.tb27007.x, PubMed 3291700
Secretin infusion in acute ischemic left ventricular failure: effects on myocardial performance and metabolism in a closed-chest dog model
J Pharmacol Exp Ther, 239 (3), 915-8
PubMed 3795050
Gastrointestinal peptides in serum and synovial fluid from patients with inflammatory joint disease
Ann Rheum Dis, 45 (8), 637-40
DOI 10.1136/ard.45.8.637, PubMed 2874778
The effect of secretin on the abdominal distribution of the cardiac output using radiolabelled microspheres in rats
Mater Med Pol, 18 (1), 12-5
PubMed 3747604
Release of gastrointestinal hormones in cardiodepressive shock
Acta Anaesthesiol Scand, 29 (4), 371-4
DOI 10.1111/j.1399-6576.1985.tb02217.x, PubMed 2861702
The origin and fall of plasma motilin during Escherichia coli endotoxin shock in pigs
Acta Physiol Scand, 123 (4), 399-404
DOI 10.1111/j.1748-1716.1985.tb07606.x, PubMed 3887842
Diurnal profiles of plasma cholecystokinin (CCK) and vasoactive intestinal polypeptide (VIP) in man
Mater Med Pol, 17 (1), 30-3
PubMed 4040993
Increased plasma levels of vasoactive intestinal polypeptide in pigs during endotoxinaemia
Eur Surg Res, 17 (2), 75-82
DOI 10.1159/000128451, PubMed 3884342
Changes in plasma levels of gastrointestinal regulatory peptides during hemorrhagic shock in pigs
Acta Chir Scand, 151 (5), 401-7
PubMed 2864773
Effects of secretin infusion on myocardial performance and metabolism in the dog
J Cardiovasc Pharmacol, 7 (6), 1183-7
DOI 10.1097/00005344-198511000-00027, PubMed 2418308
Production and evaluation of rabbit cholecystokinin (CCK)
Mater Med Pol, 17 (1), 34-8
PubMed 4033220
Lower plasma levels of some gastrointestinal peptides in Raynaud's disease. Influence of transcutaneous nerve stimulation
Gen Pharmacol, 16 (2), 153-6
DOI 10.1016/0306-3623(85)90055-2, PubMed 3873378
Portal and systemic plasma VIP and secretin during intravenous infusion of Escherichia coli endotoxin in pigs
Scand J Gastroenterol, 19 (8), 1048-52
PubMed 6398505
Radioimmunoassayable plasma motilin in man. Secretagogues, insulin-induced suppression, renal removal, and plasma components
Scand J Gastroenterol, 19 (6), 717-23
DOI 10.1080/00365521.1984.12005799, PubMed 6393315
Somatostatin release and plasma molecular somatostatin components in man
Acta Physiol Scand, 121 (3), 223-8
DOI 10.1111/j.1748-1716.1984.tb07450.x, PubMed 6433648
Vasoactive intestinal polypeptide and somatostatin in leucocytes
Scand J Clin Lab Invest, 44 (4), 347-51
DOI 10.3109/00365518409083818, PubMed 6147010
Plasma cholecystokinin (CCK) before and after a jejunoileal bypass operation in obese patients with reference to appetite regulation
Int J Obes, 8 (3), 233-6
PubMed 6746190
Adjuvant therapy of secondary peritonitis
Scand J Gastroenterol Suppl, 100, 43-6
PubMed 6435238
Release of gastrointestinal peptides during E. coli endotoxinaemia
Acta Chir Scand, 150 (7), 535-9
PubMed 6151326
PLASMA CHOLECYSTOKININ (CCK) BEFORE AND AFTER A JEJUNOILEAL BYPASS OPERATION IN OBESE PATIENTS WITH REFERENCE TO APPETITE REGULATION
Int. J. Obes., 8 (3), 233-236
Production and evaluation of VIP antibodies in rabbits
Mater Med Pol, 16 (1), 26-9
PubMed 6527569
Diurnal profile of plasma somatostatin in man
Acta Physiol Scand, 120 (1), 67-70
DOI 10.1111/j.1748-1716.1984.tb07374.x, PubMed 6144239
ADJUVANT THERAPY OF SECONDARY PERITONITIS
Scand. J. Gastroenterol., 19 100, 43-46
Mezlocillin treatment of septicemia in general hospitals
Scand J Infect Dis, 15 (1), 81-5
DOI 10.3109/inf.1983.15.issue-1.13, PubMed 6221403
The effect of insulin-induced hypoglycemia with and without atropine on plasma vasoactive intestinal polypeptide in man
Scand J Gastroenterol, 18 (1), 155-9
DOI 10.3109/00365528309181576, PubMed 6675173
Secretin exerts inhibition of the 8BrcAMP-stimulated 86Rb influx into avian red blood cells
Regul Pept, 4 (4), 221-5
DOI 10.1016/0167-0115(82)90114-8, PubMed 6293005
The effect of atropine on plasma vasoactive intestinal polypeptide after intraduodenal infusion of fat in man
Scand J Gastroenterol, 17 (3), 405-7
DOI 10.3109/00365528209182076, PubMed 7134868
[A review of gastrointestinal regulatory peptides]
Tidsskr Nor Laegeforen, 102 (3), 185-9
PubMed 7089943
Iodination with Iodo-gen and radioimmunoassay of cholecystokinin (CCK) in acidified plasma, CCK release, and molecular CCK components in man
Digestion, 23 (3), 156-68
DOI 10.1159/000198723, PubMed 7106417
Diurnal profile of plasma secretin in man
Digestion, 22 (4), 192-5
DOI 10.1159/000198644, PubMed 7198065
The effect of somatostatin on fasting and postprandial plasma GIP, serum insulin, and blood glucose in man
Scand J Gastroenterol, 16 (1), 113-9
PubMed 6112787
The effect of a 34-h fast on the meal-induced rises in plasma GIP, serum insulin, and blood glucose in man
Scand J Gastroenterol, 16 (1), 109-12
PubMed 7015476
[Indocyanine green clearance. A liver function test as sensitive as the bromsulphalein test?]
Tidsskr Nor Laegeforen, 100 (24), 1438-9
PubMed 7444890
The effect of duodenal infusion of bile on plasma VIP, GIP, and secretin and on duodenal bicarbonate secretion
Scand J Gastroenterol, 15 (8), 1007-11
DOI 10.3109/00365528009181805, PubMed 7233065
The effect of duodenal infusion of graded doses of HCL on plasma secretin and vasoactive intestinal polypeptide (VIP), and on duodenal bicarbonate secretion in man
Mater Med Pol, 12 (4), 223-8
PubMed 7266047
Diurnal variation of plasma gastric inhibitory polypeptide in man
Scand J Gastroenterol, 15 (5), 617-9
DOI 10.3109/00365528009182224, PubMed 7192431
The effect of a test meal on plasma vasoactive intestinal polypeptide (VIP), gastric inhibitory polypeptide (GIP), and secretin in man
Scand J Gastroenterol, 14 (8), 939-43
PubMed 531513
EFFECT OF A TEST MEAL ON PLASMA VASOACTIVE INTESTINAL POLYPEPTIDE (VIP), GASTRIC-INHIBITORY POLYPEPTIDE (GIP), AND SECRETIN IN MAN
Scand. J. Gastroenterol., 14 (8), 939-943
The effect of intragastric infusion of bile, meat extract, CaCl2, and ethanol on plasma VIP and gastrin and on gastric H+ and pepsin outputs
Mater Med Pol, 11 (4), 330-3
PubMed 45275
Radioimmunoassay of vasoactive intestinal polypeptide in plasma
Scand J Gastroenterol, 13 (7), 807-13
DOI 10.3109/00365527809182195, PubMed 725503
Book chapters
Health-related quality of life in patients with inflammatory bowel disease five years after the inital diagnosis
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 39(2004)4, s. 365-73
BIBSYS 051773643
Health related quality of life five years after diagnosisin a prospective follow up study of patients with inflammatory bowel disease
In Gut, British Medical Association, London, 52(2003)suppl 6, s.A40
BIBSYS 041729900
Is a more severe course of inflammatory bowel disease reflected in the patients' health related quality of life 5 years after diagnosis in a prospective follow up study?
In Gut, British Medical Association, London, 52(2003)suppl 6, s.A207
BIBSYS 041731417
Theses
A study on vasoactive intestinal polypeptide (VIP)
[I. Lygren], Oslo, 1 b. (flere pag.)
BIBSYS 853133336